Iopofosine I-131 Shows 79% Response Rate in BTKi-Resistant Waldenström Macroglobulinemia
Iopofosine I-131 achieves 79% response rate in BTKi-resistant Waldenström Macroglobulinemia patients, with median response duration of 16 months.
Voyager Gets FDA Clearance for VY1706 Gene Therapy Targeting Tau in Alzheimer’s
Voyager's VY1706 gene therapy targeting tau protein receives FDA clearance, with first-in-human dosing expected in late 2026 for early...
Immatics’ Anzu-cel Shows 56% Response Rate in Melanoma Phase 1b
Immatics' Anzu-cel demonstrates 56% response rate in melanoma Phase 1b, with 67% efficacy in uveal melanoma and median duration...
Daraxonrasib Halves Death Risk in Phase 3 Pancreatic Cancer Trial
Daraxonrasib halves death risk in Phase 3 pancreatic cancer trial, doubling median overall survival in previously treated metastatic disease.
Apalutamide Plus Hormone Therapy Cuts Prostate Cancer Metastasis Risk by 20%
Apalutamide plus hormone therapy reduced metastasis risk by 20% in high-risk prostate cancer, with nearly ninefold improvement in pathologic...
FDA Accepts NDA for Roche’s Giredestrant in Early-Stage Breast Cancer
FDA accepts NDA for Roche's Giredestrant in early-stage breast cancer, showing 30% reduction in recurrence or death versus standard...
Vorasidenib Shows 44.1-Month Median PFS in Grade 2 IDH-Mutant Glioma
Vorasidenib demonstrates 44.1-month median progression-free survival in Grade 2 IDH-Mutant Glioma, with 72% seizure reduction and durable disease control.
Elisrasib Shows 78% Response Rate in First-Line KRAS G12C NSCLC
Elisrasib achieves 78% response rate in KRAS G12C NSCLC monotherapy, outperforming first-generation inhibitors in early Phase I/II data.
HARMONi-6: Ivonescimab Plus Chemo Cuts Death Risk 34% vs PD-1 Inhibitor
Ivonescimab plus chemo reduced death risk 34% versus PD-1 inhibitor in advanced squamous NSCLC, with OS benefit sustained at...
Daraxonrasib Cuts Death Risk 60% in Phase 3 Pancreatic Cancer Trial
Daraxonrasib cuts death risk 60% in Phase 3 pancreatic cancer trial, doubling median overall survival versus chemotherapy in previously...